Phase 3 INT Data Drives Price Target to US$77, but J.P. Morgan Believes the Upside Is Overpriced

Overview

This report reassesses the probabilities of success and DCF value of Moderna's pipeline following positive Phase 3 topline data for INT in adjuvant melanoma. Despite the substantial valuation increase, J.P. Morgan believes the market has priced in too much success for the initial indication and even other potential indications, and therefore maintains an Underweight rating.

Core views

Positive Phase 3 topline data for INT in adjuvant melanoma prompted J.P. Morgan to update its Moderna model and extend the valuation horizon to December 2027. The report had already assigned a high probability of success to this indication, but it remains uncertain whether the results can be replicated across tumor types and treatment settings. It expects to assess the efficacy details and extrapolability further after the full data are released. As part of the valuation adjustment, the report no longer applies a probability-of-success discount to Moderna's economic value in adjuvant melanoma; the program previously carried an 85% probability of success. For Moderna's attributable profits from adjuvant lung, kidney, and bladder cancers, the probability of success was increased from 55% to 70%. This adjustment reflects the greater credibility that the positive melanoma data lend to adjacent adjuvant settings, but the report does not view them as proof that the results can be replicated directly across all cancer types and settings. The report is most cautious about extrapolation to metastatic disease because the greatest uncertainty remains around whether efficacy in adjuvant melanoma can extend to metastatic settings. Nevertheless, the model has begun assigning value to potential activity in metastatic disease after applying a higher risk discount; this component contributes approximately US$12 per share, or about 15% of the new price target. The new price target therefore incorporates both the substantially de-risked value of adjuvant melanoma and probability-weighted value assigned in tiers to other adjuvant indications and metastatic disease. The valuation uses a DCF incorporating forecasts for commercialized products and the risk-adjusted value of the pipeline. WACC was reduced from 10.5% to 10.0%, while the terminal growth rate remained at 0%. Combining changes in indication-specific probabilities of success, newly added value from metastatic disease, and the lower discount rate, J.P. Morgan updated its previous December 2026 price target of US$40 to a December 2027 price target of US$77. Despite the substantial price-target increase, the rating rationale remains cautious. The report notes that Moderna's shares have risen sharply: based on the data cited, absolute returns year-to-date and over 1 month, 3 months, and 12 months were 491.3%, 182.1%, 281.4%, and 524.8%, respectively, while returns relative to the S&P 500 were 478.7%, 178.7%, 276.6%, and 504.6%, respectively. The current price of US$133.32 is well above the US$77 price target. J.P. Morgan believes this rally has exceeded the de-risking value created by the INT update itself and that the market has priced in too much success in adjuvant melanoma and other settings, so it maintains its Underweight rating. Financial forecasts still show Moderna remaining loss-making and cash-consuming. Revenue from FY25A through FY28E is projected at US$1.944 billion, US$2.117 billion, US$2.174 billion, and US$2.457 billion, respectively; adjusted EBITDA at -US$3.074 billion, -US$3.333 billion, -US$1.829 billion, and -US$1.393 billion; adjusted earnings per share at -US$7.26, -US$8.04, -US$4.39, and -US$3.35; and FCFF at -US$2.065 billion, -US$2.682 billion, -US$1.411 billion, and -US$1.101 billion. Year-over-year revenue growth is expected to decline from 8.9% in FY26E to 2.7% in FY27E before rising to 13.0% in FY28E. Although losses narrow after FY27E, the company remains unprofitable throughout the forecast period, reinforcing the valuation's sensitivity to pipeline success, commercial scale, and discount-rate assumptions.

Analysis framework

The report first uses the Phase 3 topline data for INT in adjuvant melanoma as a catalyst to assess the extent to which the results can be extrapolated to other tumor types and treatment settings. It then adjusts the probabilities of success for each indication separately and applies a heavier risk discount to the more uncertain metastatic disease setting. Finally, it incorporates the probability-adjusted pipeline value and commercial-business forecasts into a DCF, discounts them using WACC and the terminal growth rate, and compares the resulting price target with the current share price and recent performance to determine the rating.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  DCF Valuation

  The report discounts forecasts for the commercial business and the risk-adjusted pipeline value to present value using a WACC of 10.0% and a terminal growth rate of 0%; WACC was previously 10.5%.

• (Out-of-Vocabulary Method)

  Probability-Weighted Pipeline Valuation

  The report incorporates economic value based on the probability of success for each clinical indication: adjuvant melanoma is no longer discounted, the probability of success for lung, kidney, and bladder cancers rises from 55% to 70%, and metastatic disease is assigned a higher risk discount.

• Event-Driven Strategy and Behavioral FinanceEvent-driven analysis

  Model Revaluation Following a Clinical Data Event

  The Phase 3 INT topline results directly triggered the model revision and price-target increase. The report also compares the value created by clinical de-risking with the post-event share-price increase to determine whether the market has fully or excessively priced in the event.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Moderna (MRNA.US)

  Positive Phase 3 data for INT in adjuvant melanoma increased the pipeline valuation, but the report believes the share price has excessively priced in the related success and the value of extrapolation to other indications.

  Strengths

  INT has a high probability of success in adjuvant melanoma; the probabilities of success for other adjuvant indications were raised; metastatic disease has begun contributing risk-adjusted valuation.

  Weaknesses

  The current share price is above the US$77 price target, and adjusted EBITDA, earnings per share, and FCFF are all negative from FY25A through FY28E.

  Comparison

  During the periods cited in the report, Moderna outperformed the S&P 500 by 478.7% year-to-date, 178.7% over 1 month, 276.6% over 3 months, and 504.6% over 12 months.

  Risks

  Risks include clinical development, regulatory, commercialization, manufacturing, financing, and intellectual property risks, as well as the risk that INT efficacy cannot be replicated across tumor types or treatment settings.

Key data

• Current PriceUS$133.32As of August 20, 2026
• New Price TargetUS$77.00December 2027 price target
• Previous Price TargetUS$40.00Previously the December 2026 price target
• Probability of Success in Adjuvant MelanomaPreviously 85%; now no longer risk-adjustedBased on positive Phase 3 INT topline data
• Probability of Success in Lung, Kidney, and Bladder Cancers70%Raised from 55%
• Valuation Contribution from Metastatic DiseaseApproximately US$12 per shareApproximately 15% of the new price target, after applying a higher risk discount
• DCF Discount Rate10.0%WACC was previously 10.5%
• DCF Terminal Growth Rate0%Price-target valuation assumption
• FY25A-FY28E RevenueUS$1.944 billion, US$2.117 billion, US$2.174 billion, US$2.457 billionCorresponding year-over-year growth rates of -39.9%, 8.9%, 2.7%, and 13.0%
• FY25A-FY28E Adjusted EBITDA-US$3.074 billion, -US$3.333 billion, -US$1.829 billion, -US$1.393 billionRemains negative throughout the forecast period, but losses narrow after FY27E
• FY25A-FY28E Adjusted EPS-US$7.26, -US$8.04, -US$4.39, -US$3.35Losses widen in FY26E and then gradually narrow
• FY25A-FY28E FCFF-US$2.065 billion, -US$2.682 billion, -US$1.411 billion, -US$1.101 billionFree cash flow remains negative throughout the forecast period
• Absolute Share-Price Performance491.3% year-to-date, 182.1% over 1 month, 281.4% over 3 months, 524.8% over 12 monthsUsed by the report to illustrate the strong share-price increase
• Performance Relative to the S&P 500478.7% year-to-date, 178.7% over 1 month, 276.6% over 3 months, 504.6% over 12 monthsSignificantly outperformed the benchmark in every period

Impact & implications

The positive Phase 3 data increased the certainty of including multiple INT indications in the valuation and substantially raised the price target through higher probabilities of success, newly added value from metastatic disease, and a lower WACC. However, the report believes the share-price increase has exceeded the value supported by these fundamental adjustments, while earnings and free cash flow remain negative throughout the forecast period. Therefore, the price-target increase does not change its Underweight conclusion.

Risks

• Moderna faces the clinical development, regulatory, commercialization, manufacturing, financing, and intellectual property risks common to the biotechnology industry.
• Efficacy in adjuvant melanoma may not be fully extrapolatable to other tumor types, treatment settings, or metastatic disease.
• An easing of market concerns about vaccine manufacturers and vaccination could pose upside risk to the Underweight view.
• If the commercial opportunities for Moderna's products are greater than expected or products receive approval sooner than expected, this could pose upside risk to the price target and rating view.
• If subsequent INT trials or other pipeline assets produce better-than-expected data, the report's current cautious assessment could face upside risk.

What to watch

• Monitor efficacy details when the full Phase 3 data for INT in adjuvant melanoma are released.
• Monitor whether the melanoma results can be extrapolated to adjuvant lung, kidney, and bladder cancers.
• Monitor evidence of INT activity in metastatic disease, as well as subsequent data from other INT trials and pipeline assets.